QA102 건성 AMD 환자 대상 II상 연구 (AMEND)
건성 연령 관련 황반변성(AMD) 대상자에서 QA102의 안전성 및 효능을 평가하는 2상, 이중 마스킹, 무작위, 위약 대조, 용량 반응 연구
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Approximately 30 sites will randomize a total of approximately 150 subjects to 1 of 3 treatment arms in a 1:1:1 ratio (50 subjects per arm). Each subject will receive either QA102 or matching placebo BID for up to 15 months.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Arizona
-
Phoenix, Arizona, 미국, 85021
- Associated Retina Consultants
-
-
California
-
Mountain View, California, 미국, 94040
- Northern California Retina Vitreous Associates Medical Group
-
Pasadena, California, 미국, 91107
- California Eye Specialists Medical Group
-
Redlands, California, 미국, 91107
- California Eye Specialists Medical Group
-
-
Colorado
-
Colorado Springs, Colorado, 미국, 80909
- Retina Consultants of Southern Colorado, P.C.
-
-
Florida
-
Deerfield Beach, Florida, 미국, 33064
- Advanced Research
-
Fort Myers, Florida, 미국, 33912
- National Ophthalmic Research Institute
-
Miami, Florida, 미국, 33143
- MedEye Associates
-
Pensacola, Florida, 미국, 32503
- Retina Specialty Institute
-
Pinellas Park, Florida, 미국, 33782
- Eye Associates of Pinellas
-
Sarasota, Florida, 미국, 34239
- Sarasota Retina Institute
-
Winter Haven, Florida, 미국, 33880
- Vitreous and Retina Consultants
-
-
Georgia
-
Marietta, Georgia, 미국, 30060
- Marietta Eye Clinic
-
-
Illinois
-
Oak Forest, Illinois, 미국, 60452
- University Retina and Macula Associates
-
-
Louisiana
-
West Monroe, Louisiana, 미국, 71291
- Northeast Louisiana dba Haik Humble Eye Center
-
-
Maryland
-
Baltimore, Maryland, 미국, 21209
- The Retina Care Center
-
Hagerstown, Maryland, 미국, 21740
- Cumberland Valley Retina Consultants
-
Hagerstown, Maryland, 미국, 21740
- Mid Atlantic Retina Specialists
-
-
Massachusetts
-
Worcester, Massachusetts, 미국, 01605
- Vitreo-Retinal Associates, P.C.
-
-
Missouri
-
St Louis, Missouri, 미국, 63144
- Retina Research Institute
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45202
- Velocity Clinical Research
-
-
Oregon
-
Eugene, Oregon, 미국, 97401
- Verum Research, LLC
-
-
Pennsylvania
-
Erie, Pennsylvania, 미국, 16507
- Erie Retina Research
-
-
Texas
-
Abilene, Texas, 미국, 79606
- Retina Research Institute of Texas
-
Austin, Texas, 미국, 78705
- Austin Research Center for Retina
-
Dallas, Texas, 미국, 75243
- AXIS Clinicals LLC / Retina of North Texas
-
Plano, Texas, 미국, 75075
- Texas Retina Associates - Plano
-
San Antonio, Texas, 미국, 78215
- San Antonio Eye Center
-
-
Utah
-
Salt Lake City, Utah, 미국, 84107
- Rocky Mountain Retina Consultants
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Subject must be able to understand and willing to sign a written informed consent form (ICF) prior to the initiation of any study-specific procedures.
- Subject must be age ≥50 years at the time of informed consent.
- Subject must be able to take oral medications and willing to record daily adherence to taking their assigned capsules.
- Subject must have adequate hematologic function, hepatic function, renal function and coagulation profile as defined in the protocol.
- Subject must be willing and able to comply with study procedures and examinations.
Specific to the Study Eye:
-
Subject must have one of the following:
- extensive intermediate-size drusen, or at least 1 large drusen, or
- GA ((not involving the foveal center point) secondary to AMD, with very limited aggregate size of total GA(s), as defined in the protocol.
-
Subject must be able to correctly identify ≥35 ETDRS letters (approximately 20/200 Snellen equivalent).
Specific to Fellow Eye:
- Subject must have a diagnosis of advanced AMD (evidence of GA and/or CNV), to be confirmed by the CRC.
Specific to Both Eyes:
- Subject must have visualizable retina, clear ocular media, and adequate pupillary dilation to ensure high-quality fundus imaging.
Key Exclusion Criteria:
- Subject received an active investigational drug within 6 weeks (or 5 half-lives of the active, whichever is longer) prior to screening for this QA102 study.
- Subject has ever received gene therapy (for any condition).
- Subject is unwilling to stop intake of Age-Related Eye Disease Studies (AREDS) vitamins for the duration of the study.
- Subject has a clinically significant systemic disease that might interfere with the study, in the judgment of the Investigator.
- Subject had major surgery within 30 days prior to Screening.
Specific to Study Eye:
- Subject has large GA, subfoveal GA, or active or inactive CNV, as confirmed by the CRC.
- Subject has GA or CNV due to causes other than AMD that that developed between Visit 1 (Screening) and Visit 2 (Randomization).
- Subject has endophthalmitis.
- Subject has a hemorrhagic or serous pigment epithelial detachment (PED) within 500 µm of the foveal center point, to be confirmed by the CRC.
- Subject has had retinal procedures or surgeries, or has a retinal pathology, such as a macular hole.
- Subject has aphakia or absence of the posterior capsule.
- Subject has ever received, whether in an interventional trial or by prescription, an FDA- approved treatment for GA. Use of such treatment during the QA102 study period also is prohibited. (Study Eye Only)
Specific to Fellow Eye:
Subject has monocular vision impairment, defined as having no light perception in the fellow eye with adequate vision in the study eye.
Specific to Either Eye:
- Subject had intraocular surgery with lens replacement within 3 months of Screening.
- Subject has any ophthalmic condition that could require surgery during the study period.
- Subject has an ocular condition that might affect adequate imaging of the retina and/or or alter visual acuity.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: QA102 200mg group
Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months |
Capsules |
|
실험적: QA102 400mg group
Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months |
Capsules |
|
위약 비교기: Placebo group
Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months |
Capsules |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change From Baseline in Soft Drusen Volume (mm3)
기간: Month 12
|
Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set |
Month 12
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Mean Rate of GA Growth
기간: Month 12
|
Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline |
Month 12
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- QA102-CS201
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .